SEATTLE -- Weight loss drugs have gained momentum as treatment for obstructive sleep apnea (OSA) at sleep clinics across the ...

Real-world results for blockbuster weight-loss meds like Ozempic, Wegovy and Zepbound aren't as impressive as those promised ...

A bipartisan group of congressional lawmakers is calling on the Trump administration to address the continued sale of illicit ...

Results also show that more than 4 in 5 (81%) of patients were prescribed a low maintenance dose of their GLP-1 drug, and ...

McDonald’s Corp. shares slipped on Tuesday after Redburn Atlantic gave the burger chain its sole sell rating, saying shifting ...

CHICAGO -- Physicians debated the idea of the American Medical Association (AMA) supporting a registry to track adverse ...

Lembas is a new b2b ingredient business that makes a peptide powder that targets the GLP-1 hormone for weight loss ...

ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA), a leader in AI-powered drug discovery and biotherapeutics, today announced ...

Omada Health shares jumped after the company made its public-market debut, propelled by Americans’ renewed focus on how ...

In that light, the GLP-1 rebound effect is not an obstacle but an opportunity to chart a new, holistic course in obesity care ...

Like in the STRIDE study of PAD, GLP-1s improved outcomes, but more work is needed to clarify who may benefit most.

A potentially blinding condition is a very rare side effect of the GLP-1 receptor agonist semaglutide (Ozempic, Wegovy, ...